Literature DB >> 27785784

Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor Argatroban.

Susan Guy1, Steve Kitchen1, Joost J Van Veen1.   

Abstract

Keywords:  activated partial thromboplastin time; argatroban; direct thrombin inhibitor; heparin induced-thrombocytopenia

Mesh：

Substances：

Year:  2016        PMID： 27785784     DOI： 10.1111/bjh.14397

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  2 in total

1.  Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients.

Authors:  Jacob T Beyer; Stuart E Lind; Sheila Fisher; Toby C Trujillo; Michael F Wempe; Tyree H Kiser
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

2.  Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT).

Authors:  Susan Guy; Steve Kitchen; Michael Makris; Rhona M Maclean; Giorgia Saccullo; Joost J Vanveen
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.